Zobrazeno 1 - 10
of 132
pro vyhledávání: '"David, Hough"'
Autor:
David Hough, Alice R. Mao, Michael Aman, Reymundo Lozano, Constance Smith-Hicks, Veronica Martinez-Cerdeno, Michael Derby, Zachary Rome, Niel Malan, Robert L. Findling
Publikováno v:
Annals of General Psychiatry, Vol 22, Iss 1, Pp 1-12 (2023)
Abstract Background There is a critical need for effective treatment of the core symptoms of autism spectrum disorder (ASD). The purinergic antagonist suramin may improve core symptoms through restoration of normal mitochondrial function and reductio
Externí odkaz:
https://doaj.org/article/1743603b9ad44d018904136d758c5761
Publikováno v:
Schizophrenia Research: Cognition, Vol 20, Iss , Pp - (2020)
Objective: To assess cognitive functioning in adolescents (12–17 years old) with schizophrenia during open-label treatment with paliperidone extended-release (pali ER). Methods: In this exploratory analysis, adolescents treated with pali ER (oral,
Externí odkaz:
https://doaj.org/article/ab59f2ffe19d4ef4a89e2a9341a2aaa6
Autor:
Pilar Lim, Husseini K. Manji, Rosanne Lane, Ella Daly, Wayne C. Drevets, Rachel Ochs-Ross, Carol Jamieson, David C. Steffens, Yun Zhang, Jaskaran Singh, David Hough, Gerard Sanacora, Ewa Wajs
Publikováno v:
The American Journal of Geriatric Psychiatry. 30:541-556
Background Older, compared with younger, patients with treatment-resistant depression (TRD) typically have lower response and remission rates with poorer tolerability to antidepressant treatment. This post-hoc analysis compared outcomes following tre
Publikováno v:
Clinical Pharmacology and Therapeutics
This post hoc analysis assessed the benefit–risk profile of esketamine nasal spray + oral antidepressant (AD) induction and maintenance treatment in patients with treatment‐resistant depression (TRD). The Benefit–Risk Action Team framework was
Autor:
David Hough, F. Reed Johnson, Shelby D. Reed, Bennett Levitan, Eva G. Katz, Angelyn O. Fairchild, Allitia DiBernardo, Jaskaran Sing
Publikováno v:
Neurology, Psychiatry and Brain Research. 37:67-78
Background Novel ketamine-based pharmacotherapies can reduce depressive symptoms among patients with treatment-resistant depression (TRD), but associated short-term symptoms and potential adverse events raise complex benefit-risk questions. Methods A
Autor:
Rosanne Lane, Wayne C. Drevets, Xin Qiu, Dong-Jing Fu, Siegfried Kasper, Dawn F. Ionescu, Carla M. Canuso, Pilar Lim, David Hough, Husseini K. Manji
Publikováno v:
International Journal of Neuropsychopharmacology
BackgroundPatients with major depressive disorder (MDD) having active suicidal ideation with intent require immediate treatment.MethodsThis double-blind study (ASPIRE II) randomized adults (aged 18–64 years) with MDD having active suicidal ideation
Autor:
David Hough, Vanina Popova, Jaskaran Singh, Maju Mathews, Maggie Fedgchin, Ella Daly, Wayne C. Drevets
Publikováno v:
The Lancet Psychiatry. 7:232-235
Autor:
Pilar Lim, Eduard Vieta, Kimberly L. Cooper, David Hough, Michael E. Thase, Jaskaran Singh, Husseini K. Manji, Christine Mazzucco, Malek Bajbouj, Patricio Molero, Richard C. Shelton, Rosanne Lane, Vanina Popova, Ella Daly, Madhukar H. Trivedi, Wayne C. Drevets
Publikováno v:
American Journal of Psychiatry. 176:428-438
Objective:About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants. This study compared the efficacy and safety of switching patients wi...
Autor:
Carla M. Canuso, Rosanne Lane, David Hough, Christine Pinter, Gerard Sanacora, Larry Alphs, Husseini K. Manji, Wayne C. Drevets, Maggie Fedgchin, Pilar Lim, Jaskaran Singh
Publikováno v:
FOCUS. 17:55-65
The authors compared the efficacy of standard-of-care treatment plus intranasal esketamine or placebo for rapid reduction of symptoms of major depression, including suicidality, among individuals at imminent suicide risk.In a double-blind, multicente
Autor:
Xiang Li, Wayne C. Drevets, Husseini K. Manji, Rosanne Lane, Carla M. Canuso, Dawn F. Ionescu, Dong-Jing Fu, Gerard Sanacora, Pilar Lim, David Hough
Publikováno v:
The Journal of Clinical Psychiatry. 81
Objective To compare esketamine to placebo, each in addition to standard-of-care treatment, for rapidly reducing major depressive disorder symptoms, including suicidal ideation. Methods This phase 3, double-blind, multicenter study (ASPIRE I), conduc